Agios Pharmaceuticals’ Sarah Gheuens sells 7,866 shares

The chief medical officer's sale was made under a Rule 10b5-1 trading plan; 16,275 options remained after the exercise.

Rhea-AI Filing Summary

Agios Pharmaceuticals, Inc. (AGIO) Chief Medical Officer Sarah Gheuens exercised options covering 7,866 shares at an exercise price of $25.01 per share on October 26, 2026, acquiring common stock, then sold 7,866 shares at a weighted average price of $37.69 per share under a Rule 10b5-1 trading plan. Sale prices ranged from $37.53 to $38.06. After the exercise, she held options covering 16,275 shares, expiring March 1, 2033.

Insider Trade Summary 10b5-1

Exercise and Sale: 7,866 shares ($100K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Gheuens Sarah

Role Chief Medical Officer

Sold 7,866 shs ($296K)

Approx. gross sale proceeds $296K

Approx. exercise cost $197K

Approx. pre-tax spread $100K

Type	Security	Shares	Price	Value
Exercise	Stock options (right to buy) F3	7,866	$0.00	$0.00
Exercise	Common stock	7,866	$25.01	$197K
Sale	Common stock F1, F2	7,866	$37.69	$296K

Holdings After Transaction: Stock options (right to buy) — 16,275 contracts (Direct); Common stock — 54,645 shares (Direct)

Footnotes (3)

1. F1. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
2. F2. The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $37.53 to $38.06. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
3. F3. This option was granted on March 1, 2023. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2024, with the remaining 75% vesting in 36 equal monthly installments thereafter.

Key Figures

Options exercised: 7,866 shares Exercise price: $25.01 per share Common shares acquired: 7,866 shares +4 more

7 metrics

Options exercised 7,866 shares October 26, 2026

Exercise price $25.01 per share Options exercised October 26, 2026

Common shares acquired 7,866 shares October 26, 2026

Shares sold 7,866 shares October 26, 2026

Weighted average sale price $37.69 per share Sale on October 26, 2026

Sale price range $37.53 to $38.06 per share Sale on October 26, 2026

Options following exercise 16,275 shares Expiration date: March 1, 2033

Key Terms

Rule 10b5-1 trading plan, weighted average, vest, Stock options (right to buy)

4 terms

Rule 10b5-1 trading plan financial

"sale was effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average financial

"price reported is the weighted average of the shares sold"

A weighted average is a way of calculating an overall number when some items matter more than others by giving each item a different level of importance, or weight. Investors use weighted averages to combine figures like prices, returns or earnings so the result reflects the size or significance of each part — like grading a class where a final exam counts more than a quiz, producing a score that better represents true performance.

vest financial

"shares underlying this option vest as to 25%"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

Stock options (right to buy) financial

"Stock options (right to buy)"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many AGIO shares did Sarah Gheuens sell, and at what price?

Sarah Gheuens sold 7,866 shares at a weighted average of $37.69 per share on October 26, 2026. The shares sold at prices ranging from $37.53 to $38.06, and the sale was effected pursuant to a Rule 10b5-1 trading plan.

What were the terms of Sarah Gheuens's AGIO option exercise?

She exercised options covering 7,866 shares at $25.01 per share on October 26, 2026. After the exercise, options covering 16,275 shares remained, with an expiration date of March 1, 2033. The option was granted March 1, 2023; 25% of its underlying shares vested on March 1, 2024, with the remaining 75% vesting in 36 equal monthly installments thereafter.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/28/2026 - 04:02 PM EDT Accepted by SEC EDGAR 10/28/2026 - 04:02 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gheuens Sarah

(Last) (First) (Middle)

88 SIDNEY STREET

(Street)

CAMBRIDGE MASSACHUSETTS 02139

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AGIOS PHARMACEUTICALS, INC. [ AGIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common stock	10/26/2026		M		7,866	A	$25.01	62,511	D
Common stock	10/26/2026		S(1)		7,866	D	$37.69(2)	54,645	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock options (right to buy)	$25.01	10/26/2026		M			7,866	(3)	03/01/2033	Common stock	7,866	$0	16,275	D

Explanation of Responses:

1. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

2. The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $37.53 to $38.06. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

3. This option was granted on March 1, 2023. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2024, with the remaining 75% vesting in 36 equal monthly installments thereafter.

Remarks:

	/s/ William Cook, as attorney-in-fact for Sarah Gheuens	10/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)